What is Zacks Research's Forecast for CRL Q2 Earnings?

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Equities researchers at Zacks Research boosted their Q2 2025 EPS estimates for shares of Charles River Laboratories International in a research report issued on Wednesday, May 28th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.46 per share for the quarter, up from their prior forecast of $2.29. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's FY2025 earnings at $9.53 EPS, Q1 2026 earnings at $2.55 EPS, Q2 2026 earnings at $2.68 EPS, Q1 2027 earnings at $2.87 EPS and FY2027 earnings at $10.93 EPS.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The medical research company reported $2.34 EPS for the quarter, topping the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million during the quarter, compared to the consensus estimate of $942.34 million. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. Charles River Laboratories International's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period last year, the firm earned $2.27 EPS.

CRL has been the topic of several other reports. JPMorgan Chase & Co. lowered their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. The Goldman Sachs Group cut shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $190.00 to $170.00 in a research note on Friday, March 21st. Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research note on Wednesday, May 14th. Mizuho lowered their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating on the stock in a research note on Wednesday, April 9th. Finally, Barclays increased their target price on shares of Charles River Laboratories International from $145.00 to $155.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 8th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of "Hold" and an average price target of $171.85.

Charles River Laboratories International Stock Performance

CRL traded down $0.70 on Monday, hitting $134.93. The company's stock had a trading volume of 510,736 shares, compared to its average volume of 994,444. The company's 50 day simple moving average is $129.03 and its 200-day simple moving average is $160.18. The firm has a market cap of $6.63 billion, a P/E ratio of 899.53, a price-to-earnings-growth ratio of 4.54 and a beta of 1.50. Charles River Laboratories International has a 12 month low of $91.86 and a 12 month high of $254.15. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65.

Institutional Investors Weigh In On Charles River Laboratories International

Several institutional investors have recently added to or reduced their stakes in CRL. Allspring Global Investments Holdings LLC boosted its holdings in shares of Charles River Laboratories International by 2.7% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock worth $330,231,000 after purchasing an additional 47,221 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Charles River Laboratories International by 46.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company's stock worth $987,000 after buying an additional 1,679 shares during the period. Boston Trust Walden Corp grew its position in shares of Charles River Laboratories International by 4.3% in the 4th quarter. Boston Trust Walden Corp now owns 204,483 shares of the medical research company's stock worth $37,748,000 after buying an additional 8,338 shares during the last quarter. E. Ohman J or Asset Management AB grew its position in shares of Charles River Laboratories International by 225.0% in the 4th quarter. E. Ohman J or Asset Management AB now owns 2,600 shares of the medical research company's stock worth $480,000 after buying an additional 1,800 shares during the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Charles River Laboratories International by 61.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company's stock valued at $84,000 after acquiring an additional 175 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Activity

In related news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total transaction of $72,705.00. Following the transaction, the executive vice president now directly owns 19,513 shares in the company, valued at $2,837,385.33. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).